Callisto Pharmaceuticals, Inc. (AMEX: KAL) is focused on developing new therapeutics that treat both cancer and gastrointestinal diseases. The Company’s management has extensive experience developing drugs for large pharmaceutical companies as well as smaller biotechnology companies.
The Company currently has three drugs in development. Guanilib is in late pre-clinical development and was purposely designed for chronic constipation, constipation-predominant irritable bowel syndrome and inflammatory bowel disease.
Atiprimod is small molecule drug drug taken orally which reveals a multiplicity of anti-cancer mechanistic activities. The drug is currently in Phase II development for advanced carcinoid cancer.
L-Annamycin is a liposome nanoparticle formulation of a second generation anthracycline. The drug could help build resistance against anthracycline-resistant tumors, and has been known to reduce cardiotoxicity. It is currently in Phase I/IIa trials for adult and children with relapsed or refractory acute leukemia.
Let us hear your thoughts: Callisto Pharmaceuticals, Inc. Message Board